Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT03755778
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03723395
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT03712540
- Locations
- 🇺🇸
PRA Health Science KK, Lenexa, Kansas, United States
Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Viriom
- Target Recruit Count
- 56
- Registration Number
- NCT03709355
- Locations
- 🇷🇺
Central Clinical City Hospital, Reutov, Moscow Region, Russian Federation
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Kevin Winthrop
- Target Recruit Count
- 474
- Registration Number
- NCT03672630
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Institute of Tropical Medicine, Belgium
- Target Recruit Count
- 144000
- Registration Number
- NCT03662022
- Locations
- 🇲🇬
Fondation Raoul Follereau, Miandrivazo, Menabe, Madagascar
🇰🇲Damien Foundation, Mohéli, Comoros
Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT03624959
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03596294
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT03586726
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT03563950
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.